ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Nitrazepam (United States: Not available): Drug information

Nitrazepam (United States: Not available): Drug information
(For additional information see "Nitrazepam (United States: Not available): Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • Mogadon
Pharmacologic Category
  • Benzodiazepine
Dosing: Adult

Dosage guidance:

Safety: Reduce dose or avoid use in patients receiving opioids. Avoid use in patients with a history of substance use, misuse of medications, or depression (Craske 2022).

Insomnia, sleep onset or sleep maintenance

Insomnia, sleep onset or sleep maintenance (alternative agent):

Note: Due to risk of next day impairment, dependence, and habituation, benzodiazepines should be reserved for patients in whom alternative, safer therapies for insomnia have failed (Neubauer 2021). When used, limit long-term use (>4 weeks) to cases for which nonpharmacologic treatments are not available or not effective and benefits are felt to outweigh risks (ACP [Qaseem 2016]; ESRS [Riemann 2017]).

Oral: Initial: 5 to 10 mg once daily at bedtime, as needed.

Discontinuation of therapy: Reduce by 25% of the original dose every 1 to 2 weeks until lowest available dose is reached, then discontinue. Patients on long-term therapy or in whom discontinuation has previously failed may benefit from a slower taper in conjunction with cognitive behavioral therapy for insomnia (Bélanger 2009).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Hepatic Impairment: Adult

Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Severe impairment: Use is contraindicated.

Dosing: Older Adult

Insomnia: Elderly or debilitated patients: Note: Avoid use (Ref). Oral: Initial: 2.5 mg once daily, as needed, at bedtime; may increase dose to 5 mg at bedtime if tolerated (maximum dose: 5 mg/day).

Dosing: Pediatric
Myoclonic seizures

Myoclonic seizures: Infants and Children ≤30 kg: Oral: Usual dosage: 0.3 to 1 mg/kg/day in 3 equally divided doses; if doses are not divided equally, administer larger dose at bedtime. Note: Therapy should be initiated below the usual dosage range and titrated carefully based on response. If inadequate response to usual dosage, may gradually increase dose further. Manufacturer labeling does not specify a maximum dosage.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Hepatic Impairment: Pediatric

Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Severe impairment: Use is contraindicated.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Postmarketing:

Cardiovascular: Hypotension, palpitations

Dermatologic: Dermatological reaction

Endocrine & metabolic: Change in libido

Gastrointestinal: Constipation, diarrhea, dyspepsia, heartburn, nausea, sialorrhea (Jan 1971), vomiting

Hematologic & oncologic: Granulocytopenia, leukopenia

Hepatic: Abnormal hepatic function tests

Hypersensitivity: Anaphylaxis, angioedema

Nervous system: Abnormal dreams (depressed dreaming), abnormality in thinking, aggressive behavior, amnesia (including anterograde amnesia), apprehension, asthenia, ataxia (Jan 1971), behavioral changes (including disinhibition, inappropriate behavior), complex sleep-related disorder (including sleep driving), confusion, depersonalization, depression, disorientation, dizziness, drowsiness (Jan 1971), drug abuse, drug dependence (Clift 1972), emotional lability, falling, fatigue, hallucination, hangover effect (Charles 1987), headache, hypothermia (Impallomeni 1976), lethargy, nervousness, nightmares (Girwood 1973), paresthesia (MacLean 1973), sedated state, staggering, suicidal ideation, suicidal tendencies, withdrawal syndrome (including catatonia, delirium, muscle rigidity, rebound anxiety, rebound insomnia, tremor) (Adam 1976; Mackinnon 1982)

Ophthalmic: Blurred vision

Respiratory: Dyspnea, increased bronchial secretions (Jan 1971)

Miscellaneous: Paradoxical reaction (Nassr 1986)

Contraindications

Hypersensitivity to nitrazepam, benzodiazepines, or any component of the formulation; myasthenia gravis; severe respiratory insufficiency (eg, significant sleep apnea syndrome); severe hepatic insufficiency; use as hypnotic in children

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylaxis/anaphylactoid reactions: Have been reported with use (rare); patients who develop angioedema should not be rechallenged with nitrazepam.

• Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999). May also rarely induce transient global amnesia or traveler's amnesia (if taken to induce sleep while traveling); caution patients to ensure they have uninterrupted sleep of 7 to 8 hours after ingestion of dose.

• Aspiration pneumonia: Bronchial hypersecretion and excessive salivation/drooling leading to aspiration pneumonia in young and elderly patients may occur rarely.

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).

• Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines; risk may be increased in adolescent/pediatric patients, geriatric patients, or patients with a history of alcohol use disorder or psychiatric/personality disorders (Mancuso 2004).

• Rebound insomnia: Following withdrawal of therapy, transient insomnia may recur accompanied by other reactions including restlessness, anxiety, and mood changes.

• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).

Disease-related concerns:

• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).

• Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.

• Hepatic impairment: Use with caution in patients with hepatic impairment (contraindicated in severe hepatic impairment).

• Renal impairment: Use with caution in patients with renal impairment.

• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression. Use is contraindicated in severe respiratory insufficiency.

• Sleep apnea: Benzodiazepines can suppress respiratory drive in patients with obstructive sleep apnea; use caution when prescribing for insomnia in this population (Webster 2020). Nitrazepam is contraindicated in cases of clinically significant sleep apnea.

Special populations:

• Debilitated patients: Use with caution in debilitated patients

• Older adult: Use with caution in older adults. Older adult patients may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older adult dementia patients (Jennum 2015; Saarelainen 2018).

• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).

• Pediatric: Associated with sudden death in children <5 years of age being treated for seizure disorders (Murphy 1987; Rintahaka 1999). Use should be restricted to children unresponsive to other antiseizure agents. Higher doses may cause excessive drowsiness and bronchial hypersecretion in infants and young children; evaluate infants prior to initiation of therapy to determine if upper airway is clear.

Other warnings/precautions:

• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.

• Hypnotic: Appropriate use: Should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7 to 10 days may indicate psychiatric and/or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation. Reassess patient for appropriateness of continued use after 2 to 3 weeks of consecutive treatment.

• Rebound insomnia: Following withdrawal of therapy, transient insomnia may recur accompanied by other reactions, including restlessness, anxiety, and mood changes.

• Tolerance: Nitrazepam is a long half-life benzodiazepine; duration of action after a single dose is determined by redistribution rather than metabolism (Brunton 2011). Tolerance develops to the hypnotic and antiseizure effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.

• Withdrawal: A longer sleep-onset latency and increased awakenings during sleep may occur for 1 to 2 days following the discontinuation of GABA-mediated (GABAergic) medications. A more severe withdrawal syndrome may rarely occur following abrupt discontinuation or large decreases in dose after sustained use (>10 days), and is characterized by new-onset agitation, ataxia, depersonalization, dizziness, dysphoria, fatigue, headache, hypersensitivity to stimuli, irritability, muscle cramps or pain, nausea, sweating, twitching, vomiting, and weakness. This withdrawal syndrome generally resolves within weeks or upon reinitiation of the GABAergic medication. Intermittent dosing may reduce the risk of withdrawal symptoms (BAP [Wilson 2019]). Use caution when reducing dose or withdrawing therapy; avoid abrupt discontinuation; decrease slowly and monitor for withdrawal symptoms.

Product Availability

Not available in the US

Generic Equivalent Available: US

May be product dependent

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Mogadon: 5 mg, 10 mg

Controlled Substance

CDSA IV

Administration: Adult

Oral: Tablets may be swallowed whole, crushed, or dissolved in liquid. For insomnia, administer at bedtime. For myoclonic seizures, administer in 3 equally divided doses, or if doses are not divided equally, give larger dose at bedtime.

Administration: Pediatric

Oral: Myoclonic seizures: Tablets may be swallowed whole, crushed, or dissolved in liquid. Administer in 3 equally divided doses, or if doses are not divided equally, give larger dose at bedtime.

Use: Labeled Indications

Note: Not approved in the United States.

Insomnia, sleep onset or sleep maintenance: Short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Limitations of use: Restrict use to insomnia that impairs normal daytime functioning. Treatment should typically not exceed 7 to 10 consecutive days. Reevaluation of the patient is required if treatment continues for >2 to 3 consecutive weeks. Prescriptions should be written for short-term use (7 to 10 days) and limited to ≤1 month supply.

Seizures: Management of myoclonic seizures in children.

Medication Safety Issues
Older Adult: High-Risk Medication:

Beers Criteria: Benzodiazepines (nitrazepam) are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined. Risk D: Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

Cosyntropin: May enhance the hepatotoxic effect of Nitrazepam. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Nitrazepam. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ilaprazole: May increase the serum concentration of Benzodiazepines. Risk C: Monitor therapy

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Melatonin: May enhance the sedative effect of Benzodiazepines. Risk C: Monitor therapy

Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone. Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution. Risk D: Consider therapy modification

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine. Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended. Risk C: Monitor therapy

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. Risk X: Avoid combination

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Teduglutide: May increase the serum concentration of Benzodiazepines. Risk C: Monitor therapy

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Yohimbine: May diminish the therapeutic effect of Antianxiety Agents. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Pregnancy Considerations

Nitrazepam crosses the placenta (Kangas 1977).

In-utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors) (Iqbal 2002). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to benzodiazepines in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal (Iqbal 2002).

Treatment for insomnia in pregnant patients should be individualized. Untreated insomnia may lead to adverse pregnancy outcomes. Although recommendations vary, nonpharmacologic therapy is preferred as an initial treatment of insomnia during pregnancy (BAP [McAllister-Williams 2017]; BAP [Wilson 2019]; Palagini 2022).

Breastfeeding Considerations

Nitrazepam is present in breast milk (Kangas 1981; Matheson 1990).

Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines, including nitrazepam (Iqbal 2002; Speight 1977).

Breastfeeding during benzodiazepine therapy is not recommended due to the potential for drowsiness in the breastfed infant (Larsen 2015). Breastfeeding is not recommended by the manufacturer. Infants exposed to nitrazepam via breast milk should be monitored for adverse events, including irritability and sedation.

Monitoring Parameters

Respiratory, cardiovascular, and mental status

Reference Range

Steady state levels after 4 days: 40 ng/mL

Mechanism of Action

Intermediate-acting benzodiazepine (based on half-life) (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: 20 to 50 minutes.

Absorption: Rapid.

Duration of action: Classified as an intermediate-acting benzodiazepine; classification based on benzodiazepines with half-life of 12 to 40 hours (Griffin 2013).

Distribution: Vd: 2.4 L/kg (range: 1.6 to 3.2 L/kg), Elderly: 4.8 L/kg (range: 3.1 to 6.5 L/kg); also distributes into CSF, saliva (Kangas 1979).

Protein binding: 87%.

Metabolism: Hepatic: Nitroreduction, acetylation; no active metabolites.

Bioavailability: ~80%.

Half-life elimination: 30 hours (range: 18 to 57 hours), Elderly/ill patients: 40 hours.

Time to peak, plasma: ~3 hours.

Excretion: Urine (65% to 71%, ~1% as unchanged drug); feces (14% to 20%).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Mogadon | Somnite;
  • (AT) Austria: Mogadon;
  • (AU) Australia: Alodorm | Mogadon;
  • (BD) Bangladesh: Amoctin | Epam | Eunoctin | Noctin | Relactin;
  • (BE) Belgium: Mogadon | Nitrazepam teva generics belgium;
  • (BG) Bulgaria: Berlidorm | Radedorm;
  • (BR) Brazil: Nitrapan | Nitrazepol | Sonebon;
  • (CH) Switzerland: Mogadon;
  • (DE) Germany: Dormalon | Dormalon nitrazepam | Imeson | Mogadon | Nitrazepam al | Novanox;
  • (DO) Dominican Republic: Hipnotab | Quill;
  • (EC) Ecuador: Somnil;
  • (EE) Estonia: Berlidorm | Dima-10 | Eatan n | Eunoctin | Nitrazepam accord | Nitrazepam-alpharma | Nomefren | Radedorm;
  • (ES) Spain: Nitrazepan;
  • (FI) Finland: Apodorm | Insomin | Mogadon | Nitrazepam accord | Pacisyn | Somitran;
  • (FR) France: Mogadon;
  • (GB) United Kingdom: Mogadon | Nitrados | Nitrazepam almus | Nitrazepam arrow | Nitrazepam berk | Nitrazepam dc | Nitrazepam kent | Nitreeze | Noctesed | Remnos | Somnased | Somnite | Unisomnia;
  • (HK) Hong Kong: Dima | Mogadon | Nipa;
  • (HR) Croatia: Cerson;
  • (HU) Hungary: Eunoctin;
  • (ID) Indonesia: Dumolid | Mogadon | Somnil;
  • (IE) Ireland: Mogadon | Somnite;
  • (IL) Israel: Numbon;
  • (IN) India: Baronite | Calmtra | Dormin | Halonite | Hypnoril | Manonit | Nicare | Nidra | Nigap | Nipam | Nira | Nitavan | Nitcalm | Nite | Nithra | Nitpro | Nitraplan | Nitravet | Nitrosun | Nitrosym | Niz | Stressban;
  • (IT) Italy: Mogadon;
  • (JP) Japan: Benzalin | Calsmin | Chiorazepam | Cysvon | Hirusukamin | Nelbon | Nelmat | Nelurolen | Nemnamine | Neuchlonic | Nitrazepam amel | Nitrazepam bmj | Nitrazepam nichiiko | Nitrazepam okura | Nitrazepam teva | Nitrazepam towa | Nitrazepam zensei;
  • (KR) Korea, Republic of: Mogadon;
  • (LB) Lebanon: Mogadon;
  • (LT) Lithuania: Berlidorm | Eunoctin | Imeson | Nitrazepam bp | Radedorm;
  • (LU) Luxembourg: Mogadon;
  • (LV) Latvia: Berlidorm | Eunoctin | Imeson | Nitrazepam accord | Radedorm | Sleep;
  • (MY) Malaysia: Mogadon | Nitramin | Nitrapam;
  • (NL) Netherlands: Mogadon | Nitrazepam A | Nitrazepam Actavis;
  • (NO) Norway: Apodorm | Mogadon | Nitrazepam accord;
  • (NZ) New Zealand: Insoma | Nitrados;
  • (PK) Pakistan: Mogadon | Nitpam;
  • (PL) Poland: Nomefren | Radedorm;
  • (RU) Russian Federation: Berlidorm | Eunoctin | Nitrosan | Nozepam | Radedorm;
  • (SA) Saudi Arabia: Mogadon;
  • (SE) Sweden: Apodorm | Dumolid | Mogadon | Nitrazepam recip;
  • (SG) Singapore: Dima | Nitrados;
  • (SI) Slovenia: Cerson;
  • (TH) Thailand: Alodorm | Eunoctin | Mogadon | Nitrados;
  • (TN) Tunisia: Mogadon;
  • (TR) Turkey: Mogadon;
  • (TW) Taiwan: An-sleeper | Answet | Hirusukamin | Limin | Mogadon | Mudamin | Nitraze | Nitromin | Osmin | Sleep | Sleepin | Slomin | Susui;
  • (UA) Ukraine: Berlidorm | Eunoctin | Nitrosun | Radedorm;
  • (UY) Uruguay: Mogadon;
  • (VE) Venezuela, Bolivarian Republic of: Mogadon | Onirema;
  • (ZA) South Africa: Arem | Mogadon
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Adam K, Adamson L, Brezinová V, Hunter WM. Nitrazepam: lastingly effective but trouble on withdrawal. Br Med J. 1976;1(6025):1558-1560. doi:10.1136/bmj.1.6025.1558 [PubMed 179657]
  3. Bélanger L, Belleville G, Morin C. Management of hypnotic discontinuation in chronic insomnia. Sleep Med Clin. 2009;4(4):583-592. doi:10.1016/j.jsmc.2009.07.011 [PubMed 20607118]
  4. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003 [PubMed 23044244]
  5. Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill Medical; 2011.
  6. Charles RB, Kirkham AJ, Guyatt AR, Parker SP. Psychomotor, pulmonary and exercise responses to sleep medication. Br J Clin Pharmacol. 1987;24(2):191-197. doi:10.1111/j.1365-2125.1987.tb03161.x [PubMed 3620293]
  7. Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention- deficit/hyperactivity disorders. JAMA Netw Open. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282 [PubMed 36413366]
  8. Clift AD. Factors leading to dependence on hypnotic drugs. Br Med J. 1972;3(5827):614-617. doi:10.1136/bmj.3.5827.614 [PubMed 5071698]
  9. Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 19, 2022.
  10. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005 [PubMed 18998740]
  11. Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. Gen Hosp Psychiatry. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010 [PubMed 29958100]
  12. Girwood RH. Nitrazepam nightmares. Br Med J. 1973;1(5849):353. doi:10.1136/bmj.1.5849.353 [PubMed 4685632]
  13. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214-223. [PubMed 23789008]
  14. Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta- analysis. J Clin Psychiatry. 2019;80(4):18r12412. doi:10.4088/JCP.18r12412 [PubMed 31294935]
  15. Impallomeni M, Ezzat R. Letter: Hypothermia associated with nitrazepam administration. Br Med J. 1976;1(6003):223-224. doi:10.1136/bmj.1.6003.223-c [PubMed 1247796]
  16. Iqbal MM, Sobhan T, Ryals T, et al. Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant. Psychiatr Serv. 2002;53(1):39-49. [PubMed 11773648]
  17. Jan JE, Riegl JA, Crichton JU, Dunn HG. Nitrazepam in the treatment of epilepsy in childhood. Can Med Assoc J. 1971;104(7):571-575. [PubMed 5550546]
  18. Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. Eur Neuropsychopharmacol. 2015;25(11):1906-1913. doi:10.1016/j.euroneuro.2015.08.014 [PubMed 26342397]
  19. Kangas L, Allonen H, Lammintausta R, et al. Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. Acta Pharmacol Toxicol (Copenh). 1979;45(1):20-24. [PubMed 474154]
  20. Kangas L, Breimer DD. Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet. 1981;6(5):346-366. doi:10.2165/00003088-198106050-00002 [PubMed 7037262]
  21. Kangas L, Kanto J, Erkkola R. Transfer of nitrazepam across the human placenta. Eur J Clin Pharmacol. 1977;12(5):355-357. doi:10.1007/BF00562451 [PubMed 598407]
  22. Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. doi:10.1111/acps.12479 [PubMed 26344706]
  23. MacKinnon GL, Parker WA. Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse. 1982;9(1):19-33. doi:10.3109/00952998209002608 [PubMed 6133446]
  24. MacLean H. Nitrazepam: another interesting syndrome. Br Med J. 1973;1(5851):488. doi:10.1136/bmj.1.5851.488-b [PubMed 4689857]
  25. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185. [PubMed 15460178]
  26. Matheson I, Lunde PK, Bredesen JE. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects. Br J Clin Pharmacol. 1990;30(6):787-793. doi:10.1111/j.1365-2125.1990.tb05443.x [PubMed 2288825]
  27. McAllister-Williams RH, Baldwin DS, Cantwell R, et al; endorsed by the British Association for Psychopharmacology. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519-552. doi:10.1177/0269881117699361 [PubMed 28440103]
  28. Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; August 2021.
  29. Murphy JV, Sawasky F, Marquardt KM, et al. Deaths in Young Children Receiving Nitrazepam. J Pediatr. 1987;111(1):145-147. [PubMed 3598778]
  30. Nassr DG. Paradoxical response to nitrazepam in a patient with hypersomnia secondary to nocturnal myoclonus. J Clin Psychopharmacol. 1986;6(2):121-122. [PubMed 3700699]
  31. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol. 1999;6(2):69-83. [PubMed 10519733]
  32. Neubauer DN. Pharmacotherapy for insomnia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 10, 2021.
  33. Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. PLoS Med. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945 [PubMed 35235572]
  34. Palagini L, Bramante A, Baglioni C, et al. Insomnia evaluation and treatment during peripartum: a joint position paper from the European Insomnia Network task force "Sleep and Women," the Italian Marcè Society and international experts task force for perinatal mental health. Arch Womens Ment Health. 2022;25(3):561-575. doi:10.1007/s00737-022-01226-8 [PubMed 35419652]
  35. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. doi:10.7326/M15-2175 [PubMed 27136449]
  36. Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. Neurotoxicol Teratol. 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005 [PubMed 28259732]
  37. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700. doi:10.1111/jsr.12594 [PubMed 28875581]
  38. Rintahaka PJ, Nakagawa JA, Shewmon DA, et al. Incidence of Death in Patients with Intractable Epilepsy During Nitrazepam Treatment. Epilepsia. 1999;40(4):492-496. [PubMed 10219277]
  39. Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. Int J Geriatr Psychiatry. 2018;33(4):583-590. doi:10.1002/gps.4821 [PubMed 29143367]
  40. Speight AN. Floppy-infant syndrome and maternal diazepam and/or nitrazepam. Lancet. 1977;2(8043):878. doi:10.1016/s0140-6736(77)90817-0 [PubMed 72227]
  41. Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and Z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. JAMA Netw Open. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889 [PubMed 36520439]
  42. Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. Depress Anxiety. 2022;39(12):751-759. doi:10.1002/da.23280 [PubMed 35909254]
  43. Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. Birth Defects Res. 2019;111(10):613-620. doi:10.1002/bdr2.1497 [PubMed 30891943]
  44. US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea. https://www.healthquality.va.gov/guidelines/CD/insomnia/VADoDSleepCPGFinal508.pdf. Published October 2019. Accessed April 16, 2020.
  45. Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? Adv Pharmacol Sci. 2012;2012:1-19. [PubMed 22536226]
  46. Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. Neurosci Biobehav Rev. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647 [PubMed 35367514]
  47. Webster LR, Karan S. The physiology and maintenance of respiration: a narrative review. Pain Ther. 2020;9(2):467-486. doi:10.1007/s40122-020-00203-2 [PubMed 33021707]
  48. Wikner BN, Stiller CO, Bergman U, et al. Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203-1210. [PubMed 17894421]
  49. Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. J Psychopharmacol. 2019;33(8):923-947. doi:10.1177/0269881119855343 [PubMed 31271339]
Topic 10165 Version 240.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟